Dear Fellow Investor,
On December 13, 2022, a Big Pharma giant quietly bought one AI-designed drug for $4 billion.
That makes it the biggest deal for an AI-designed drug in history.
But very few people even know about it...yet.
Even leading investors in the U.S. have no idea.
And they don't know that this tiny AI-biotech designed the drug.
But this won't stay quiet much longer.
On January 9, 2023, ristol Myers Squibb signed a $2.7 billion deal to have their AI-platform develop six new drugs.
On October 6, 2022, Eli Lilly signed a $425 million deal to have their AI-platform develop a new drug.
These seven drugs alone could bring $28 billion to this little-known company.
That doesn't include deals they signed with Sanofi, Nimbus Therapeutics, Petra Pharma and others.
Wall Street doesn't yet grasp how this company is quietly revolutionizing the drug discovery business...
Which is why I believe this will be the biggest AI winner you never heard of.
"The Buck Stops Here,"
This message is a paid advertisement sent on behalf of Behind the Markets, a third-party advertiser of MarketBeat. Why did I receive this email?
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2023 American Consumer News, LLC dba MarketBeat.
326 E 8th St #105, Sioux Falls, SD 57103. United States.
没有评论:
发表评论